2026-08-23T19:34:25Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1324882026-02-18T00:52:40Zcom_20.500.14352_14col_20.500.14352_15

Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain Aladro, Yolandra Terrero, Rodrigo Cerezo García, Marta Ginestal, Rocardo Ayuso, Lucía Meca-Lallana, Virginia Millán, Jorge Borrego, Laura Martinez-Ginés, Marisa Rubio, Luisa De Andrés, Clara Miralles, Ambrosio Guijarro, Cristina Rodríguez-García, Elena García-Dominguez, José Manuel Muñoz-Fernández, Carmen López de Silanes, Carlos Gómez, Mayra Thuissard, Israel Cerdán, María Palmí, Itziar Díaz-Garzón, Luis Felipe Meca-Lallana, José Objective: To estimate the seroprevalence of anti-JCV antibodies, seroconverting rates and evolution of antibody levels in a multiple sclerosis (MS) Spanish cohort. Methods: Multicenter, retrospective cross-sectional and longitudinal study. The JCV seroprevalence was analyzed in 711 MS patients by using 1st (STRATIFY-1) and 2nd generation (STRATIFY-2) two-step ELISA over 2.65 (±0.97) years. Seroconversion rate was obtained over 2 samples from 314 patients, and index stability from 301 patients with 3 or more samples available. The effect of each ELISA generation, demographics, clinical characteristics and therapy on seroprevalence was assessed by logistic regression. Results: The overall anti-JCV seroprevalence was 55.3% (51.6–58.9), similar across regions (p = 0.073). It increased with age (p b 0.000) and when STRATIFY-2 was used (60.5%, p = 0.001). Neither sex nor immunosuppressive therapy had any influence. Yearly seroconversion rate was 7% (considering only STRATIFY-2). Serological changes were observed in 24/301 patients, 5.7% initially seropositive reverted to seronegative and 7% initially seronegative changed to seropositive and again to seronegative, all these cases had initial index values around the assay's cut-off. Conclusions: JCV seroprevalence in Spanish MS patients was similar to that reported in other European populations. Changes in serostatus are not infrequent and should be considered in clinical decisions. 2026-02-17T12:13:39Z 2026-02-17T12:13:39Z 2026-02-17T12:13:39Z 2016-06 journal article https://hdl.handle.net/20.500.14352/132488 0022-510X 10.1016/j.jns.2016.03.050 1878-5883 eng Aladro, Y., Terrero, R., Cerezo, M., Ginestal, R., Ayuso, L., Meca-Lallana, V., Millán, J., Borrego, L., Martinez-Ginés, M., Rubio, L., De Andrés, C., Miralles, A., Guijarro, C., Rodríguez-García, E., García-Dominguez, J. M., Muñoz-Fernández, C., López De Silanes, C., Gómez, M., Thuissard, I., et al. (2016). Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort JC virus seroprevalence in Spain. Journal of the Neurological Sciences, 365, 16-21. https://doi.org/10.1016/J.JNS.2016.03.050 http://creativecommons.org/licenses/by-nc-sa/4.0/ restricted access Attribution-NonCommercial-ShareAlike 4.0 International Elsevier